anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
CARDENE SR is a sustained release formulation of CARDENE . CARDENE SR capsules for oral administration each contain 30 mg, 45 mg or 60 mg of nicardipine hydrochloride. Nicardipine hydrochloride is a calcium ion influx inhibitor (slow channel blocker or calcium entry blocker). ®®

Nicardipine hydrochloride is a dihydropyridine derivative with the IUPAC (International Union of Pure and Applied Chemistry) chemical name (±)-2-(benzyl-methyl amino) ethyl methyl 1,4-dihydro-2,6 dimethyl-4-(m-nitrophenyl)-3, 5-pyridinedicarboxylate monohydrochloride, and it has the following structure:

Nicardipine hydrochloride is a greenish-yellow, odorless, crystalline powder that melts at about 169°C. It is freely soluble in chloroform, methanol and glacial acetic acid, sparingly soluble in anhydrous ethanol, slightly soluble in n-butanol, water, 0.01 M potassium dihydrogen phosphate, acetone and dioxane, very slightly soluble in ethyl acetate, and practically insoluble in benzene, ether and hexane. It has a molecular weight of 515.99.

CARDENE SR is available in hard gelatin capsules containing 30 mg, 45 mg or 60 mg nicardipine hydrochloride. All strengths contain a two component capsule fill. A powder component containing 25% of total nicardipine hydrochloride dose contains pregelatinized starch and magnesium stearate as inactive ingredients. A spherical granule component containing 75% of total nicardipine hydrochloride dose also contains microcrystalline cellulose, starch, lactose and methacrylic acid copolymer Type C as inactive ingredients.

The colorants used in the 30-mg capsules are titanium dioxide, FD&C Red No. 40 and red iron oxide, and the colorants used in the 45-mg and 60-mg capsule are titanium dioxide and FD&C Blue No. 2.
PURPOSE:To obtain a hair dyeing agent having excellently dyeing properties free from stain on one's skin, dyeing the hair in light color tone, containing water-soluble dye, dyeing assistant ana an oxidizing agent, by adjusting pH of the dyeing agent to specific alkalinity. CONSTITUTION:A hair dyeing agent containing 0.001-10wt.% water-soluble dye, 1-30wt.% dyeing assistant and 1-30wt.% oxidizing agent (e.g. hydrogen peroxide). Besides these components, the hair dyeing agent is properly mixed with well-known compounding additives such as surfactant, thickening agent, ultraviolet light absorber and perfume, further blended with a pH adjuster such as ammonia water or ammonium sulfate and adjusted to pH7.5-11 to give the objective substance. The substance can be prepared into a form such as powder, aqueous solution, gel, paste, cream, aerosol and aerosol foam. Benzyl alcohol or N-methylpyrrolidone may be cited as the dyeing assistant.
In observational studies, small daily doses of lithium have been associated with a 77% reduced risk of developing Parkinson's disease (PD). In addition, lithium therapy has been effective in preventing neuronal death and behavioral symptoms in several PD animal models. Recently, our group has shown 24-weeks of low-dose lithium therapy in PD to improve both MRI and blood-based biomarkers implying that lithium may be slowing the progression of the disease. However, these findings stem from only three of four patients receiving MRIs. A larger study will be required to determine if these promising results can be replicated. The proposed study will enroll 20 additional PD patients who will be randomly assigned to receive either lithium 20mg/day or identically-appearing placebo capsules for 24 weeks. This will be a double-blind study meaning that neither the patients nor the study team will know to which therapy patients have been assigned. Positive results from this study will support further research on lithium that could eventually support lithium as a disease-modifying therapy for PD that could improve patients' long-term prognoses.
Stress-induced premature senescent (SIPS) cells induced by various stresses deteriorate cell functions. Dasatinib and quercetin senolytics (DQ) can alleviate several diseases by eliminating senescent cells. α-tricalcium phosphate (α-TCP) is a widely used therapeutic approach for bone restoration but induces bone formation for a comparatively long time. Furthermore, bone infection exacerbates the detrimental prognosis of bone formation during material implant surgery due to oral cavity bacteria and unintentional contamination. It is essential to mitigate the inhibitory effects on bone formation during surgical procedures. Little is known that DQ improves bone formation in Lipopolysaccharide (LPS)-contaminated implants and its intrinsic mechanisms in the study of maxillofacial bone defects. This study aims to investigate whether the administration of DQ ameliorates the impairments on bone repair inflammation and contamination by eliminating SIPS cells. α-TCP and LPS-contaminated α-TCP were implanted into Sprague-Dawley rat calvaria bone defects. Simultaneously, bone formation in the bone defects was investigated with or without the oral administration of DQ. Micro-computed tomography and hematoxylin-eosin staining showed that senolytics significantly enhanced bone formation at the defect site. Histology and immunofluorescence staining revealed that the levels of p21- and p16-positive senescent cells, inflammation, macrophages, reactive oxygen species, and tartrate-resistant acid phosphatase-positive cells declined after administering DQ. DQ could partially alleviate the production of senescent markers and senescence-associated secretory phenotypes in vitro. This study indicates that LPS-contaminated α-TCP-based biomaterials can induce cellular senescence and hamper bone regeneration. Senolytics have significant therapeutic potential in reducing the adverse osteogenic effects of biomaterial-related infections and improving bone formation capacity.
The initial phase of the study will be a dose escalation of hydroxychloroquine from 600 mg to 1,200 mg orally flat dose given 2 hours before the CPI-613 infusion on days 1-5 of every 28 days. CPI-dose will be 2,000 mg/m² and will not be escalated.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgery and oncology, and can be used for the prevention of bleeding and metastasis in the radical surgical treatment of malignant neoplasms of the chest and abdominal cavity. For doing this determine the spinous process of the twelfth thoracic vertebra in the preoperative period in the sitting position of the patient, straightening. Stepping to the left of its spinous process by 2.5–3.0 cm, skin anesthesia and deeper-lying tissues are produced with a local anesthetic with a conventional injection needle. Further using a needle sort of Tuohy, moving the edges along the upper edge to the midline of the body, reach the transverse process of the twelfth thoracic vertebra. Bypass it laterally and from above, pushing the needle into the retroperitoneal space to the site of the formation of the thoracic lymphatic duct. Install the catheter. Further, in the preoperative stage, 40 minutes before the surgery, Lydazum 32 U, diluted in 2 ml of 0.25 % novocaine, is administered once through in-line catheter. Then after 5–10 minutes, 2 ml of Dicynone is administered once. After the next 5–10 minutes, 2 ml of Midodrine is administered once. Perform radical surgical treatment for malignant neoplasms. Perform lymphadenectomy. In the postoperative stage, Lydazum 32 U, diluted in 2 ml of 0.25 % novocaine, is administered 1 times a day through in-line catheter, on the 1st and 2nd days. Then after 5–10 minutes, 2 ml of Dicynone is administered. After 5–10 minutes, 2 ml of Midodrine is administered.EFFECT: method provides an increase in the radicalism of surgical treatment and effective prevention of bleeding and spreading of metastases due to the lymphotropic administration of the hemostatic medication and adrenergic mimetic procedure in the retroperitoneal space to the site of formation of the thoracic lymphatic duct.1 cl, 1 ex
PURPOSE: A tablet containing herb extract of Clematis florida, Trichosanthes kirilowii and Prunella vulgaris var. is provided to shorten disintegration time and to easily manufacture. CONSTITUTION: A tablet containing extract of florida, Trichosanthes kirilowii and Prunella vulgaris var. contains crosscarmellose sodium as a disintegrant. The tablet contains anhydrous dibasic calcium phosphate as an excipient. The composition 30-70 weight% of the herb extract, 7-15 weight% of crosscarmellose sodium, 6-14 weight% of anhydrous dibasic calcium phosphate, and 15-45 weight% of additional excipient of lactose, microcrystalline cellulose, powder cellulose, starch or pregelatinized starch.
PURPOSE:To effectively utilize a stone in UME (plum) subjected to disposal treatment by using powder prepared by pulverizing an endocarp contained in the stone in the UME within a wide range of a scrubbing cosmetic, a face washing cream, a dentifrice, massage powder, an abrasive material, etc. CONSTITUTION:A stone in UME is washed and then dried. The dried stone in the UME is then pulverized with a pulverizer, etc., and separated into an endocarp and an embryo. The endocarp is further pulverized to 10mum to 1mm size to afford stone powder of the UME. The stone powder of the UME having 150mum to 1mm size is added at 1-10% weight ratio and especially used as a scrubbing cosmetic (the touch is improved by removing a keratinous part or a fouled part of the skin). The stone powder of the UME having 10-80mum size at 5-10% weight ratio is added and used as a face washing cream and the stone powder of the UME having 10-80mum size at 1-10% weight ratio is added in the case of a dentifrice. The stone powder of the UME having 10-80mum size at 5-10% weight ratio is added in the case of massage powder. Furthermore, the stone powder of the UME having 80mum to 1mm size is used in the case of an abrasive material.
Living attenuated oral vaccine comprises an effective dose of a genetic hybrid deriv.(s) of an attenuated galactose epimerase-free mutant strain of Salmonella typi and a Shigella strain protective antigen carried by it. Genetic hybrid deriv. of an attenuated galactose epimerase-free mutant strain of S.typhi and a Shigella strain protective antigen carried by it is new. The vaccines are effective for oral immunisation against only a single (non-typhoid) enteric disease or simultaneously against more than one enteric disease, and it can confer protection against both typhoid fever and against bacillary dysentery due to S.sonnei. The vaccines produce antigens effective in protecting against S.sonnei and S. flexneri serotypes causing over 90% of all Shigellosis worldwide.
The patent relates to a computer implemented method for early diagnosis of diabetes mellitus type 2 (T2DM) and β-pancreatic cell loss monitoring. The method employs Machine Learning tools to identify specific biomarkers related to circulating cell-free DNA (ccfDNA) to build accurate diagnostic/monitoring predictive biosignatures/models for clinical application. The models are further enriched with demographical/lifestyle/pathological/clinical subject data to achieve higher discriminating capacity. AutoML analysis of data delivered a five-feature biosignature, including GCK. IAPP and KCNJ11 gene methylation identified in ccfDNA and age and BMI, accurately discriminating T2DM patients from healthy individuals. This leads to a methylation-specific PCR based methodology for diagnosis/prognosis/monitoring of T2DM using liquid biopsy biomaterial.
Methods and systems for managing drug usage are provided. In an embodiment, reminder data associated with a drug treatment plan of a patient is accessed. The reminder data includes a reminder time indicia and a patient identifier associated with the patient. The drug treatment plan is associated with a drug to be taken by the patient. A determination of whether a reminder criterion of the prescription drug treatment plan has been met is made based on the reminder time indicia. A patient messaging configuration is accessed based on the patient identifier. A notification is generated based on a determination that the reminder criterion has been met and the patient messaging configuration. Additional methods and systems are disclosed.
Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days. Minnelide™ Capsules should be given with the patient in a fasting state.
This arm includes the Family Food \& Lifestyle + Family Dynamics interventions (FL+FD). Parents and children meet separately for the full 90-minute psychoeducation sessions. The first 45 minutes are devoted to the Family Food \& Lifestyle intervention and the second 45 minutes to the Family Dynamics intervention.
Following the discovery of circulating tumor cells (CTCs) in the peripheral blood of cancer patients, CTCs were initially postulated to hold promise as a valuable prognostic tool through liquid biopsy. However, a decade and a half of accumulated data have revealed significant complexities in the investigation of CTCs. A challenging aspect lies in the reduced expression or complete loss of key epithelial markers during the epithelial-mesenchymal transition (EMT). This likely hampers the identification of a pathogenetically significant subset of CTCs. Nevertheless, there is a growing body of evidence regarding the prognostic value of such molecules as CD24 expressing in the primary breast tumor. Herewith, the exact relevance of CD24 expression on CTCs remains unclear. We used two epithelial markers (EpCAM and cytokeratin 7/8) to assess the count of CTCs in 57 breast cancer patients, both with (M0mts) and without metastasis (M0) during the follow-up period, as well as in M1 breast cancer patients. However, the investigation of these epithelial markers proved ineffective in identifying cell population expressing different combinations of EpCAM and cytokeratin 7/8 with prognostic significance for breast cancer metastases. Surprisingly, we found CD24+ circulating cells (CCs) in peripheral blood of breast cancer patients which have no epithelial markers (EpCAM and cytokeratin 7/8) but was strongly associated with distant metastasis. Namely, the count of CD45-EpCAM-CK7/8-CD24+ N-cadherin-CCs was elevated in both groups of patients, those with existing metastasis and those who developed metastases during the follow-up period. Simultaneously, an elevation in these cell counts beyond the established threshold of 218.3 cells per 1 mL of blood in patients prior to any treatment predicted a 12-fold risk of metastases, along with a threefold decrease in distant metastasis-free survival over a 90-month follow-up period. The origin of CD45-EpCAM-CK7/8-CD24+ N-cadherin-CCs remains unclear. In our opinion their existence can be explained by two most probable hypotheses. These cells could exhibit a terminal EMT phenotype, or it might be immature cells originating from the bone marrow. Nonetheless, if this hypothesis holds true, it's worth noting that the mentioned CCs do not align with any of the recognized stages of monocyte or neutrophil maturation, primarily due to the presence of CD45 expression in the myeloid cells. The results suggest the presence in the peripheral blood of patients with metastasis (both during the follow-up period and prior to inclusion in the study) of a cell population with a currently unspecified origin, possibly arising from both myeloid and tumor sources, as confirmed by the presence of aneuploidy.
OBJECTIVES: Early shock reversal is crucial to improve patient outcomes. Capillary refill time (CRT) is clinically important to identify and monitor shock in children but has issues with inconsistency. To minimize inconsistency, we evaluated a CRT monitoring system using an automated compression device. Our objective was to determine proper compression pressure in children.
METHODS: Clinician force for CRT was collected during manual CRT measurement as a reference for automated compression in a previous study (12.9 N, 95% confidence interval, 12.5-13.4; n = 454). An automated compression device with a soft inflation bladder was fitted with a force sensor. We evaluated the effectiveness of the automated pressure to eliminate pulsatile blood flow from the distal phalange. Median and variance of CRT analysis at each pressure was compared.
RESULTS: A comparison of pressures at 300 to 500 mm Hg on a simulated finger yielded a force of 5 to 10 N, and these pressures were subsequently used for automated compression for CRT. Automated compression was tested in 44 subjects (median age, 33 months; interquartile range [IQR], 14-56 months). At interim analysis of 17 subjects, there was significant difference in the waveform with residual pulsatile blood flow (9/50: 18% at 300 mm Hg, 5/50:10% at 400 mm Hg, 0/51: 0% at 500 mm Hg, P = 0.008). With subsequent enrollment of 27 subjects at 400 and 500 mm Hg, none had residual pulsatile blood flow. There was no difference in the CRT: median 1.8 (IQR, 1.06-2.875) in 400 mm Hg vs median 1.87 (IQR, 1.25-2.8325) in 500 mm Hg, P = 0.81. The variance of CRT was significantly larger in 400 mm Hg: 2.99 in 400 mm Hg vs. 1.35 in 500 mm Hg, P = 0.02, Levene's test. Intraclass correlation coefficient for automated CRT was 0.56 at 400 mm Hg and 0.78 at 500 mm Hg.
CONCLUSIONS: Using clinician CRT measurement data, we determined either 400 or 500 mm Hg is an appropriate pressure for automated CRT, although 500 mm Hg demonstrates superior consistency.
Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2).
BACKGROUND: Breast cancer with about 2.3 million diagnoses and 685,000 deaths globally is the most frequent malignancy in the female population. Continuous research has led to oncological and reconstructive advances in the management of breast cancer, thus improving outcomes and decreasing patient morbidity. Nowadays, the submuscular expander and prosthesis (E/P) implant-based breast reconstruction (IBR) accounts for 73% of all reconstructions. Despite its widely accepted efficacy, the technique is not free from complications and up to 28% of cases require revision surgery for mechanical complications such as capsular contracture, implant displacement/rotation, and implant rupture. With this study, the authors report their experience in the management of E/P IBR revision surgery through the technique of Selective Capsulotomies (SCs) and Partial Capsulectomy (PC).
METHODS: A retrospective study was conducted on patients who had previously undergone E/P IBR and presented for revision reconstruction between January 2013 and May 2023 at the Department of Plastic Surgery of the University of Siena, Italy. Reasons for revision included capsular contracture, implant displacement/rotation, and implant rupture. Revision reconstructions involved SC and PC with implant replacement. Fat grafting was also considered. The complication rate was evaluated by analysis of patients' medical records. Patients' satisfaction with the treatment was assessed through a specific questionnaire.
RESULTS: 32 patients underwent revision surgeries. No early complication occurred. Recurrence rate was assessed at 19% with average follow-up of 59 months (range: 13-114 months). The average time between revision surgery and recurrence was 3 years (range: 1-6 years). 23 patients answered the questionnaire and were overall satisfied with the treatments (8.29/10).
CONCLUSIONS: SC possibly associated to PC is a valuable option for E/P IBR revision surgery with minimal complications, reduced surgical trauma, short operating time, and relatively low recurrence risk. In addition, treated patients are overall satisfied with the results over time.
1,190,386. Lactic acid bacteria preparations. GREEN CROSS CORP. 4 May, 1967 [28 June, 1966], No. 20832/67. Heading A5B. [Also in Division C6] Lactic acid) bacteria highly resistant to antibiotics (specified) are cultured and propagated in a liquid culture medium, sterilized starch is added to the bacteria culture suspension obtained so as to absorb the lactic acid bacteria on the starch, dry starch is added to the bacteria-absorbed starch until the mixture has the appearance of dry starch powder and druigs for intestinal use are prepared therefrom. The lactic acid bacteria are cultivated in the culture medium (initial pH 6.3-6.8) at a temperature of 36‹-39‹C. for about 48 hours. The bacteria are then absorbed on potato starch (or corn starch) previously sterilized with ethylene oxide and further dry starch is added until an apparently dry dust is obtained. The bacteriacontaining starch dust is filled into gelatine capsules and the capsules are coalted firstly with a 10% ethanol solution of polyvinyl pyrroilidone and subsequently with a 10% methyl ethyl ketone solution of cellulose acetate phthalate. Polyvinyl alcohol monophthalic ester and polyethylene glycol are also mentioned. Lactic acid bacteria: Lactobacillus acidophilus, Lactobacillus lactis and Streptococcus lactis.
The presence of CD8+ T cells in the cytoplasm of biliary epithelial cells (BEC) has been correlated with biliary damage associated with primary biliary cholangitis (PBC). Here, we characterise the mechanism of CD8+ T cell invasion into BEC. CD8+ T cells observed within BEC were large, eccentric, and expressed E-cadherin, CD103 and CD69. They were also not contained within secondary vesicles. Internalisation required cytoskeletal rearrangements which facilitated contact with BEC. Internalised CD8+ T cells were observed in both non-cirrhotic and cirrhotic diseased liver tissues but enriched in PBC patients, both during active disease and at the time of transplantation. E-cadherin expression by CD8+ T cells correlated with frequency of internalisation of these cells into BEC. E-cadherin+ CD8+ T cells formed β-catenin-associated interactions with BEC, were larger than E-cadherin- CD8+ T cells and invaded into BEC more frequently. Overall, we unveil a distinct cell-in-cell structure process in the liver detailing the invasion of E-cadherin+ CD103+ CD69+ CD8+ T cells into BEC.
Young adults exhibit an increasing prevalence of obesity, pre-diabetes, and metabolic syndrome that contribute to increased risk of type II diabetes and cardiovascular heart disease later in life. Twenty five percent of American adults have been diagnosed with metabolic syndrome, whereas the prevalence increases to 30 % in Mexican American adults between 30-70 years old. The risk in this population may be higher based on ethnicity and the rising obesity rates in young adults and children, although the definition of metabolic syndrome in younger age has yet to be established. Factors causing metabolic syndrome are complex but include a physically inactive lifestyle, an unhealthy diet made up of saturated fat and processed foods, and inherited influences. Therefore identifying the need to intervene early with a dietary intervention in order to combat the risk for future disease is vital. It is hypothesized that 8 weeks supplementation of alpha lipoic acid (known superantioxidant already produced by the body) will significantly improve metabolic syndrome markers (e.g., excess body weight, blood pressure, glucose, insulin, blood lipids, and self-report measures) in young (18-25 years) overweight or obese males compared to placebo (cellulose starch). If the hypothesis is supported, alpha lipoic acid ingestion could be beneficial in reducing disease risk and enhancing metabolic dysfunction in young individuals. Therefore, the purpose is to establish the impact alpha lipoic acid has on the modifiable markers associated with metabolic perturbations consistent with metabolic syndrome in males.
Gain-framed message. In this 59-second video advertisement, the emphasis is on highlighting the gains associated with quitting smoking. The narrative follows a female protagonist who, one year after quitting, meets with her physician. The physician highlights the client's improved lung X-ray and blood test results compared to the previous year, offering congratulations on the decision and celebrating the positive health outcome. Encouraged by this progress, the client is motivated to continue making positive lifestyle choices.